- ￥440 - 1320
- CUSABIO
- CN
- CSB-PA08129A0Rb
- 2025年07月10日
- ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200
- Rabbit
- Human
企业认证
相关产品推荐更多 >
Gfap抗体Gfap兔多抗抗体GFAP antibody抗体Gfap Antibody抗体
￥440
DRP2抗体DRP2兔多抗抗体Dystrophin-related protein 2 antibody抗体DRP2 Antibody抗体
￥440
KLHL42抗体KLHL42兔多抗抗体Kelch domain-containing protein 5 antibody抗体KLHL42 Antibody抗体
￥440
MRPL34抗体MRPL34一抗抗体Mitochondrial large ribosomal subunit protein bL34m antibody抗体MRPL34 Antibody抗体
￥3900TBC1D22A抗体TBC1D22A兔多抗抗体TBC1 domain family member 22A antibody抗体TBC1D22A Antibody, HRP conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Tumor necrosis factor receptor superfamily member 3 protein (31-224AA)
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
Polyclonal
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
P36941
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200
- 浓度：
>95%,Protein G purified
- 靶点：
LTBR
- 抗体英文名：
LTBR Antibody
- 抗体名：
Tumor necrosis factor receptor type III antibody
- 规格：
100μg/50μg/20μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
| 规格： | 20μg | 产品价格： | ￥440.0 |
保存缓冲液
Preservative: 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
功能
/风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验. We isolated a variant of Herceptin, a therapeutic monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), on the basis of its ability to simultaneously interact with vascular endothelial growth factor (VEGF). Crystallographic
Collagen-Induced Arthritis in Mice: A Major Role for Tumor Necrosis Factor-
arthritis, including tumor necrosis factor-α (TNFα) and interleukin (IL)-1β, IL-6, IL-1Ra, IL-10, and transforming growth factor β. The use transgenic and knockout strains of mice, as well as biological inhibitors, have revealed important pathological roles
of rheumatoid arthritis. Arthritis Res Ther. 2024 Dec 19;26(1):216. [4] Buttgereit F, et al. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe
技术资料暂无技术资料 索取技术资料
